LAUSR

The present study conducted a placebo‐controlled clinical trial to evaluate the impact of nano‐curcumin on the inflammatory cytokines in mild‐to‐moderate hospitalized COVID‐19 patients. A total of 60 COVID‐19 patients were randomly divided into nano‐curcumin and control groups, and then they received 240 mg/day nano‐curcumin for 7 days. The clinical manifestation and laboratory parameters in patients were recorded on days 0 and seven. Also, SYBR Green real‐time PCR and ELISA techniques were implicated in assessing the mRNA expression of IFN‐γ, IL‐1β, IL‐6, MCP‐1, and TNF‐α and the serum levels of IL‐1β, IL‐6, and TNF‐α inflammatory mediators, respectively. Although the clinical manifestations and laboratory parameters improved via the nano‐curcumin treatment, the mRNA expression of IFN‐γ (p = 0.006) and TNF‐α (p = 0.04) were significantly reduced. Besides, a considerable difference was observed between the nano‐curcumin and control groups in the expression of IFN‐γ (p = 0.001), IL‐1β (p = 0.0002), and IL‐6 (p = 0.008). In addition, there was a significant difference between the nano‐curcumin and control groups in the serum levels of IL‐1β (p = 0.042). The evidence demonstrated that nano‐curcumin could be implicated as a complementary medication to act as an antiinflammatory agent and inhibit inflammatory complications.